Literature DB >> 8988171

UBE3A/E6-AP mutations cause Angelman syndrome.

T Kishino1, M Lalande, J Wagstaff.   

Abstract

Angelman syndrome (AS), characterized by mental retardation, seizures, frequent smiling and laughter, and abnormal gait, is one of the best examples of human disease in which genetic imprinting plays a role. In about 70% of cases, AS is caused by de novo maternal deletions at 15q11-q13 (ref. 2). Approximately 2% of AS cases are caused by paternal uniparental disomy (UPD) of chromosome 15 (ref. 3) and 2-3% are caused by "imprinting mutations'. In the remaining 25% of AS cases, no deletion, uniparental disomy (UPD), or methylation abnormality is detectable, and these cases, unlike deletions or UPD, can be familial. These cases are likely to result from mutations in a gene that is expressed either exclusively or preferentially from the maternal chromosome 15. We have found that a 15q inversion inherited by an AS child from her normal mother disrupts the 5' end of the UBE3A (E6-AP) gene, the product of which functions in protein ubiquitination. We have looked for novel UBE3A mutations in nondeletion/non-UPD/non-imprinting mutation (NDUI) AS patients and have found one patient who is heterozygous for a 5-bp de novo tandem duplication. We have also found in two brothers a heterozygous mutation, an A to G transition that creates a new 3' splice junction 7 bp upstream from the normal splice junction. Both mutations are predicted to cause a frameshift and premature termination of translation. Our results demonstrate that UBE3A mutations are one cause of AS and indicate a possible abnormality in ubiquitin-mediated protein degradation during brain development in this disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988171     DOI: 10.1038/ng0197-70

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  417 in total

1.  Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination.

Authors:  H Oda; S Kumar; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 2.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

Review 3.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

Review 4.  Ubiquitin-mediated proteolysis in learning and memory.

Authors:  D G Chain; J H Schwartz; A N Hegde
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

Review 5.  Close yet so far away: a look into the management strategies of genetic imprinting disorders.

Authors:  Mark A Pianka; Alec T McIntosh; Sahaj D Patel; Pegah R Bakhshi; Mira Jung
Journal:  Am J Stem Cells       Date:  2018-10-01

6.  The human aminophospholipid-transporting ATPase gene ATP10C maps adjacent to UBE3A and exhibits similar imprinted expression.

Authors:  L B Herzing; S J Kim; E H Cook ; D H Ledbetter
Journal:  Am J Hum Genet       Date:  2001-05-11       Impact factor: 11.025

Review 7.  New views of Arc, a master regulator of synaptic plasticity.

Authors:  Jason D Shepherd; Mark F Bear
Journal:  Nat Neurosci       Date:  2011-01-30       Impact factor: 24.884

8.  Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.

Authors:  S Nakagawa; J M Huibregtse
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 9.  Rett syndrome and MeCP2: linking epigenetics and neuronal function.

Authors:  Mona D Shahbazian; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2002-11-19       Impact factor: 11.025

10.  Narrowed abrogation of the Angelman syndrome critical interval on human chromosome 15 does not interfere with epigenotype maintenance in somatic cells.

Authors:  Masayuki Haruta; Makiko Meguro; Yu-Ki Sakamoto; Hidetoshi Hoshiya; Akiko Kashiwagi; Yasuhiko Kaneko; Kohzoh Mitsuya; Mitsuo Oshimura
Journal:  J Hum Genet       Date:  2005-03-03       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.